Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 04, 2026
TickeronGET DAILY SIGNALS
Royalty Pharma (RPRX) Posts +9% Rise in Q3 Portfolio Receipts and Raises Guidance

Royalty Pharma (RPRX) Posts +9% Rise in Q3 Portfolio Receipts and Raises Guidance

Key Takeaways

  • Royalty Pharma reported third quarter 2026 Portfolio Receipts of $890 million, up 9% from $814 million a year earlier.
  • Royalty Receipts — the company's recurring cash inflows — rose 9% to $883 million and grew 12% through the first nine months of 2026.
  • Reported earnings of $1.21 per share exceeded the $1.18 consensus, while GAAP net income fell to $145 million, weighed down by a $150 million non-cash impairment tied to Novartis' pelacarsen.
  • Management raised full-year 2026 Portfolio Receipts guidance for the third consecutive quarter, to $3.50 billion–$3.55 billion, implying Royalty Receipts growth of 10%–11%.
  • Royalty Pharma added three new royalties during the quarter — Zoryve, Mimrylo, and cliramitug — bringing 2026 announced transaction value to $1.9 billion.
  • Adjusted EBITDA was $840 million, and Portfolio Cash Flow reached $673 million.

Why These Results Matter

Royalty Pharma's third quarter results matter because the company's entire business model depends on the durability and diversification of its royalty portfolio. As a royalty aggregator, Royalty Pharma collects payments tied to sales of therapies developed by partners rather than selling drugs itself. Investors closely watch whether growth from newer franchises such as Tremfya, Voranigo, Evrysdi, and Imdelltra can offset structural declines in legacy royalties like Promacta and Imbruvica. The quarter also carried portfolio-specific risks, including the failed Phase 3 trial for Novartis' pelacarsen. Against that backdrop, the results offered a direct read on management's ability to redeploy cash into value-enhancing royalty acquisitions while sustaining shareholder returns through dividends and buybacks. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

The Quarter in Detail

For the third quarter ended September 30, 2026, Royalty Pharma reported Portfolio Receipts of $890 million, a 9% increase from $814 million in the prior-year period. Royalty Receipts rose 9% to $883 million, driven by strong performances from Tremfya, Voranigo, Evrysdi, and Imdelltra, which absorbed an approximately 5% combined headwind from declines in Promacta and Imbruvica.

On a GAAP basis, total income and other revenues were $690 million, up 13.3% year over year. Reported earnings were $1.21 per share, modestly above the $1.18 consensus. Net income attributable to the company fell to $145 million from $284 million a year earlier, primarily reflecting a $150 million non-cash impairment charge related to pelacarsen.

Adjusted EBITDA was $840 million, up 8% from $779 million, while Portfolio Cash Flow rose 2% to $673 million. Net cash provided by operating activities slipped 2% to $686 million. Management raised its full-year 2026 Portfolio Receipts outlook to $3.50 billion–$3.55 billion, up from $3.40 billion–$3.50 billion, implying Royalty Receipts growth of 10%–11%.

Market Reaction and Investor Sentiment

Royalty Pharma shares edged lower following the report despite results that topped earnings-per-share expectations and a third consecutive guidance increase. The muted reaction reflected investor focus on several cross-currents. The GAAP revenue line of $690 million landed well below consensus estimates near $876 million, though analysts attributed much of that gap to a mismatch between the cash-based Portfolio Receipts metric and the accounting-based revenue figure. The $150 million pelacarsen impairment and the decline in GAAP net income also weighed on sentiment. Meanwhile, the slowdown in quarterly Royalty Receipts growth — from double-digit levels earlier in 2026 to 9% in Q3 — prompted some investors to weigh deceleration against the still-strong year-to-date performance.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will watch whether Royalty Pharma's newer royalty assets can continue offsetting erosion in legacy products. Growth drivers such as Tremfya, Voranigo, Evrysdi, and Imdelltra have carried the portfolio so far, but Promacta and Imbruvica declines remain a structural drag that management must absorb while sustaining double-digit Royalty Receipts growth.

Guidance will be a central focus. The raised full-year 2026 range of $3.50 billion–$3.55 billion implies Royalty Receipts growth of 10%–11%, and excludes any benefit from future acquisitions. Investors will also track capital deployment, with $1.9 billion in announced transactions this year, including royalties on Zoryve, Mimrylo, and cliramitug.

Beyond the numbers, several catalysts could shape sentiment in the months ahead. An upcoming FDA regulatory decision on GSK's neladalkib and Phase 3 results for Biogen's litifilimab in systemic lupus are among the near-term clinical events management highlighted. Margin trends and the timing of interest payments also bear watching, given that Portfolio Cash Flow margins dipped in the quarter largely due to the semi-annual debt-payment schedule. Return metrics remained stable, with return on invested capital at 14.3% and return on invested equity at 20.2% over the trailing twelve months. From what I see, the balance between new acquisitions and legacy offsets remains the key variable to track.

Using AI Tools in My Research

I often turn to Tickeron’s AI Screener when reviewing earnings like these. It helps me quickly filter healthcare royalty names and compare technical signals, fundamentals, and performance trends against peers. This approach gives me a clearer view of where Royalty Pharma stands relative to similar holdings without spending hours on manual screens.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: RPRX

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Aroon Indicator for RPRX shows an upward move is likely

RPRX's Aroon Indicator triggered a bullish signal on November 11, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 268 similar instances where the Aroon Indicator showed a similar pattern. In 188 of the 268 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 70%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on RPRX as a result. In 51 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.

The Moving Average Convergence Divergence (MACD) for RPRX just turned positive on October 14, 2026. Looking at past instances where RPRX's MACD turned positive, the stock continued to rise in 30 of 50 cases over the following month. The odds of a continued upward trend are 60%.

RPRX moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for RPRX crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 47%.

Following a +1.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where RPRX advanced for three days, in 174 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 14 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 20 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RPRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 49%.

RPRX broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 16 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. RPRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.386) is normal, around the industry mean (3.498). P/E Ratio (35.989) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (1.360) is also within normal values, averaging (9.059). Dividend Yield (0.014) settles around the average of (130.981) among similar stocks. P/S Ratio (12.870) is also within normal values, averaging (440.869).

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -0%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was -14%. PEPG experienced the highest price growth at 115%, while KPTI experienced the biggest fall at -76%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -22%. For the same stocks of the Industry, the average monthly volume growth was 23% and the average quarterly volume growth was -37%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 43
Price Growth Rating: 66
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of drug development services

Industry Biotechnology

Industry
Pharmaceuticals Major
Address
110 East 59th Street
Phone
+1 212 883-0200
Employees
100
Web
https://www.royaltypharma.com
Interact to see
Advertisement
AtlasClear Holdings (ATCH) shares fell roughly 25.5% over the last 30 days, declining from $0.1881 on October 2 to $0.1401 on October 30. The pullback extended a longer downtrend that has kept the stock trading well below the $1.00 NYSE American minimum, keeping continued listing-compliance risk in focus.
Nebius Group N.V. is expected to report third-quarter 2026 results in early November, following a second quarter in which revenue surged 454% year over year. Wall Street consensus tracked by Benzinga points to roughly $937 million in Q3 2026 revenue, up from $146.1 million in the year-ago quarter.
The $1.14 central target is not an analyst consensus; it is the all-cash merger consideration in GoPro, Inc. (GPRO) 's pending deal with Starman Optical, agreed in September 2026. With the stock trading near $0.88, reaching $1.14 would require a move of roughly 29.5%.
NVDA fell -2.10% to $216.66 during regular trading, down from a prior close of $221.30. Primary catalyst: hotter-than-expected September CPI data reignited Fed rate-hike fears, raising borrowing costs for AI infrastructure buildouts.
The central target of $1,620 is the arithmetic mean of verified, current analyst price targets, rounded to a clean level; it is not a single firm's forecast or a guarantee. At a recent price of about $690 , reaching $1,620 would require a gain of roughly 135% , a very large move by any standard.
Royalty Pharma (RPRX) Posts +9% Rise in Q3 Portfolio Receipts and Raises Guidance